Overcoming FVIII Inhibitors With Efanesoctocog Alfa – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Aqsa Ashraf et. al, adding:
“Successful immune tolerance induction using efanesoctocog alfa in severe hemophilia A: a case series
Two patients with severe hemophilia A and complex inhibitor histories underwent immune tolerance induction with efanesoctocog alfa at 100 U/kg three times weekly.
Inhibitor titers became undetectable within six weeks and three months, with FVIII recovery above 90%.
Once-weekly prophylaxis maintained troughs of 4-6% and bleed-free outcomes, allowing emicizumab discontinuation.”
Title: Successful immune tolerance induction using efanesoctocog alfa in severe hemophilia A: a case series
Authors: Aqsa Ashraf, Rebekah Kuhlman, Osman Khan, Sanober Nusrat
Stay updated with Hemostasis Today.
-
Oct 4, 2026, 14:41David McIntosh: International Plasma Awareness Week 2026 – Closing the Global Plasma Gap
-
Oct 4, 2026, 14:33Pete Stibbs: CleanerVac Real-World Study Presented at VIVA and The VEINS 2026
-
Oct 4, 2026, 13:56Maria Elisa Mancuso: EHC 2026 Highlights the Unmet Needs of Women with Bleeding Disorders
-
Oct 4, 2026, 13:53Nirmal Shaji George: Individualizing Anticoagulation in Complex APS and Thrombocytopenia
-
Oct 4, 2026, 13:5210 Posts Not to Miss This Week
-
Oct 4, 2026, 13:45Suswapna Singh Rawat: The Clinical Significance of Coronary Plaque Stability
-
Oct 4, 2026, 13:35Sumyea Kabir: Optimizing Plasma Selection for Therapeutic Plasma Exchange in TTP
-
Oct 4, 2026, 13:31Swati Raikwar: Microplastics as a Threat to Cerebral Blood Flow
-
Oct 4, 2026, 13:18Maria Elisa Mancuso: EHC 2026 Opens with Focus on Haemophilia Care, Access and Rare Disorders